Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...
Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Up to 33.1% of adults eligible for GLP-1 receptor ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Orforglipron, an oral GLP-1, reduced HbA1c more than ...
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses ...
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study This phase III randomized trial (VIKTORIA-1; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results